CONCORDBIO - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | CONCORDBIO | Market Cap | 11,947 Cr. | Current Price | 1,142 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 37.6 | Book Value | 174 ₹ | Dividend Yield | 0.94 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,114 ₹ | DMA 200 | 1,351 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.36 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 61.9 | MACD | -1.21 | Volume | 3,20,331 | Avg Vol 1Wk | 5,43,102 |
| Low price | 987 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.40 | Debt to equity | 0.00 |
| 52w Index | 13.3 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 30.1 |
📊 CONCORDBIO is trading above its 50 DMA (1,114 ₹) but below the 200 DMA (1,351 ₹), indicating short-term strength but medium-term weakness. RSI at 61.9 suggests moderate bullish momentum, while MACD at -1.21 reflects weak momentum and possible consolidation. Current volume (3,20,331) is below average (5,43,102), showing reduced participation. Bollinger Bands suggest price stabilizing near mid-range, hinting at consolidation rather than a breakout.
🎯 Entry Zone: 1,130 ₹ – 1,145 ₹ (support near 1,114 ₹)
💰 Exit Zone: 1,170 ₹ – 1,190 ₹ (resistance near 1,190 ₹)
🔄 Trend Status: Consolidating with weak momentum
Positive
- Strong ROCE (28.4%) and ROE (21.4%) highlight efficiency.
- Zero debt-to-equity ensures financial stability.
- EPS of 30.1 ₹ supports earnings strength.
- FII holdings increased (+0.21%), showing foreign investor confidence.
Limitation
- Trading below 200 DMA indicates medium-term weakness.
- MACD negative (-1.21) shows weak momentum.
- Quarterly profit variation (-5.20%) reflects earnings volatility.
- DII holdings declined (-0.36%), showing domestic investor caution.
Company Negative News
- No major negative news reported; earnings volatility remains a concern.
Company Positive News
- Quarterly PAT growth (70.2 Cr vs 62.9 Cr) shows operational improvement.
- Strong fundamentals with zero debt and efficiency ratios.
Industry
- Industry P/E at 30.1 suggests CONCORDBIO is trading at a premium (P/E 37.6).
- Biopharma sector remains volatile but supported by long-term demand.
Conclusion
⚡ CONCORDBIO is consolidating with weak momentum. Entry around 1,130–1,145 ₹ offers limited upside, with exit targets at 1,170–1,190 ₹. Strong fundamentals support long-term stability, but medium-term weakness and earnings volatility warrant cautious accumulation.
This gives you a short-term technical view. Would you like me to extend this into a medium-to-long-term investment outlook with sector benchmarking and growth projections for CONCORDBIO?